TTENK/calls
The BriefMarketsAll StocksNewsScreenerFeedback

Get the Brief in your inbox

A daily, SEC-grounded read on the market — movers, earnings, and our boldest calls. Free.

TTENK/calls

SEC-grounded equity research — opinionated calls reasoned over real filings.

Research

  • The Brief
  • Markets
  • All Stocks
  • Screener
  • Discover
  • Research
  • The Flip Side
  • Track record

Tools

  • Compare
  • Congress trades
  • Events
  • Filing search
  • Options calculator
  • Leaderboards
  • Insider trades
  • 13F funds
  • Groups
  • Trending
  • News

More

  • Pricing
  • Feedback
  • Newsletter
  • Developers / API
  • Account
DisclosuresTermsPrivacy

Research & education only — not financial advice.TENK is not a registered investment adviser; calls are impersonal, generated from SEC filings and a delayed/third-party price feed, and may be wrong or out of date. The operator and an affiliated trading operation may hold or trade the securities TENK rates — see Disclosures. Do your own research.

EDGAR® is a registered trademark of the U.S. Securities and Exchange Commission. TENK/calls is an independent service and is not affiliated with, endorsed by, or approved by the U.S. Securities and Exchange Commission.

TTENK/calls
The BriefMarketsAll StocksNewsScreenerFeedback

Pulling SEC filings + quote and writing the call…

TTENK/calls
The BriefMarketsAll StocksNewsScreenerFeedback
Home›COYA›Financials
Annual statements · SEC XBRL · FY2021 – FY2025

Coya Therapeutics, Inc. (COYA) financials

Income statement

Coya Therapeutics, Inc. (COYA) income statement, annual, from SEC filings
Fiscal yearFY2021FY2022FY2023FY2024FY2025
Revenue—$0.00$6.00M$3.55M$7.95M
Revenue growth———-40.8%123.6%
Operating income-$4.87M-$9.81M-$7.90M-$17.2M-$22.6M
Operating margin——-131.7%-485.4%-283.9%
Net income-$4.89M-$12.2M-$7.99M-$14.9M-$21.2M
Net margin——-133.1%-418.7%-267.1%
EPS (diluted)-$1.89-$4.73-$0.79-$0.98-$1.27

Cash flow

Coya Therapeutics, Inc. (COYA) cash flow, annual, from SEC filings
Fiscal yearFY2021FY2022FY2023FY2024FY2025
Operating cash flow-$3.90M-$7.24M-$11.2M-$10.3M-$10.7M

Balance sheet

Coya Therapeutics, Inc. (COYA) balance sheet, annual, from SEC filings
Fiscal yearFY2021FY2022FY2023FY2024FY2025
Cash & equivalents$4.34M$5.93M$32.6M$38.3M$46.8M
Total assets$4.79M$8.40M$41.3M$44.3M$50.0M
Total liabilities$1.15M$16.8M$5.63M$4.77M$6.92M
Shareholders' equity$3.64M-$8.39M$35.6M$39.6M$43.0M
Retained earnings-$5.62M-$17.9M-$25.9M-$40.7M-$62.0M
Shares (wtd avg diluted)2.59M2.59M10.2M15.2M16.7M

Every figure is extracted from Coya Therapeutics, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.

Common questions

What is Coya Therapeutics, Inc.'s annual revenue?
Coya Therapeutics, Inc. (COYA) reported $7.95M of revenue for fiscal year 2025 — up 123.6% from $3.55M in FY2024, per its annual report filed with the SEC.
Is Coya Therapeutics, Inc. profitable?
Not in FY2025 — COYA reported a net loss of $21.2M, per SEC filings.
Does COYA pay a dividend?
Coya Therapeutics, Inc. reported no cash dividends paid in FY2025, per its SEC cash-flow statement.
Full COYA analysis — verdict, score & filings →Is COYA a buy? →

Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.